JPMorgan analyst Jessica Fye lowered her price target for BioCryst Pharmaceutical to $5 from $10 saying the topline Phase III results for APeX-2 remove both the best-case and worst-case scenarios for BCX7353. The safety data removed a key downside risk, but BCX7353 will probably not be as large as it might have been with better efficacy, Fye tells investors in a research note. The analyst now models peak prophylaxis sales of ~$300M. However, she still sees share upside over time following yesterday's selloff and maintains an Overweight rating on BioCryst.